Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Otonomy gives up on experimental tinnitus drug after disappointing Phase 2 trial

By Brian Buntz | August 1, 2022

OtonomyNeurotology-focused biopharma Otonomy (Nasdaq:OTIC) will cease development of OTO-313 after the experimental drug failed to show clinically meaningful benefit in a randomized, placebo-controlled Phase 2 trial.

The company’s lead asset, OTO-313, did not meet either primary or secondary endpoints in the study, which involved 152 patients with persistent, unilateral tinnitus of at least moderate severity.

OTO-313 is a formulation of the selective N-methyl-D-aspartate (NMDA) receptor antagonist gacyclidine.

The San Diego–based company’s share price dropped almost 80% in mid-day trading to $0.31. On March 13, 2015, its stock price hit an all-time high of $39.36.

[Related: Researcher: Neuroinflammation may be behind tinnitus reports in some COVID-19 vaccine recipients]

The primary endpoint was related to an at least 13-point improvement on the Tinnitus Functional Index (TFI) one month and two months following treatment. For context, the TFI breaks tinnitus severity into five categories. At the bottom, a score of 0–17% indicates that tinnitus is not a problem. Conversely, a score of 73–100% means that the condition represents a very big problem.

A total of 77 recipients received an intratympanic injection of OTO-313, while the other 75 received a placebo.

Clinical trial investigators followed the patients for 4 months.

“These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” said David A. Weber, president and CEO of Otonomy.

After ceasing the development of OTO-313, Weber noted that the company would “implement other measures to extend our cash runway.”

Otonomy plans to focus on the hearing loss drug candidate OTO-413.

The company announced positive data from a Phase 2a study in April.


Filed Under: ENT drugs
Tagged With: OTO-313, Otonomy, tinnitus drug
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Decibel Therapeutics
Decibel Therapeutics touts progress with lead gene therapy product candidate DB-OTO
Otonomy
Investigational tinnitus drug shows promise in Phase 1/2 study
Decibel Therapeutics
Decibel Therapeutics announces study on noise-related inner ear damage

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50